Barrington Research Reiterates Outperform Rating for OPKO Health (NASDAQ:OPK)

OPKO Health (NASDAQ:OPK)‘s stock had its “outperform” rating reiterated by equities research analysts at Barrington Research in a research report issued on Thursday,Benzinga reports. They presently have a $2.25 price target on the biotechnology company’s stock. Barrington Research’s price objective points to a potential upside of 65.44% from the company’s current price.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, October 8th. Zacks Research raised shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. Finally, LADENBURG THALM/SH SH upgraded OPKO Health to a “strong-buy” rating in a report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $2.28.

OPKO Health Stock Down 6.8%

Shares of NASDAQ:OPK opened at $1.36 on Thursday. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $1.08 billion, a P/E ratio of -5.44 and a beta of 1.50. OPKO Health has a 52-week low of $1.11 and a 52-week high of $2.04. The stock’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $1.38.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.05. The firm had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $165.74 million. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The firm’s quarterly revenue was down 12.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 EPS. As a group, equities research analysts forecast that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average price of $1.32 per share, with a total value of $891,000.00. Following the completion of the transaction, the chief executive officer owned 214,676,448 shares of the company’s stock, valued at approximately $283,372,911.36. This trade represents a 0.32% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 49.69% of the company’s stock.

Institutional Trading of OPKO Health

Institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC increased its holdings in shares of OPKO Health by 29.1% during the 2nd quarter. Brighton Jones LLC now owns 38,916 shares of the biotechnology company’s stock worth $51,000 after buying an additional 8,775 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in OPKO Health by 4.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company’s stock valued at $262,000 after acquiring an additional 8,954 shares during the period. 360 Financial Inc. increased its stake in OPKO Health by 12.0% during the second quarter. 360 Financial Inc. now owns 88,800 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 9,500 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in OPKO Health by 11.2% during the second quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company’s stock worth $183,000 after acquiring an additional 13,912 shares during the last quarter. Finally, Oak Thistle LLC purchased a new position in shares of OPKO Health in the 1st quarter worth about $26,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.